A Phase 2 interventional study of HOE901-U300 (new formulation of insulin glargine) and Lantus (insulin glargine) in Type 1 Diabetes Mellitus, sponsored by Sanofi. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-06-01.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 40th largest by enrollment, is one of 8 that started in 2012, is one of 3 in phase 2, and was the 37th registered.
3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is above the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 73 across the 66 interventional studies. Of the 63 that completed or were terminated, 24 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 66 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
67 studies in Diabetes Mellitus, Type 1 by Sanofi: 6 open now, 9 under way, 1 of them phase 3. Of 57 finished, 13 (23%) have results posted.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 35th largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2012, is one of 5 in phase 2, and was the 29th registered.
Sanofi’s Diabetes Mellitus, Type 1 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 67 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 millimole per liter (mmol/L).
Drug: HOE901-U300 (new formulation of insulin glargine)
HOE901-U300 (new insulin glargine 300 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
Drug: HOE901-U300 (new formulation of insulin glargine)
Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
Drug: Lantus (insulin glargine)
Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
Drug: Lantus (insulin glargine)
Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL])
Percentage of time with glucose within glycemic range (4.4-7.8 mmol/L) was assessed by the total time within glycemic range divided by the length of the assessment interval.
Time frame: Up to Week 16 (assessed at Weeks 7-8 in Period A and Weeks 15-16 in Period B)
Percentage of Time Above the Upper Limit of Glycemic Range (Greater Than [>] 7.8 mmol/L [(140 mg/dL])
Percentage of time with glucose above the upper limit of glycemic range (\>7.8 mmol/L) was assessed by the total time above the upper limit of glycemic range divided by the length of the assessment interval.
Time frame: Up to Week 16 (assessed at Weeks 7-8 in Period A and Weeks 15-16 in Period B)
Percentage of Time Below The Lower Limit of Glycemic Range (<4.4 mmol/L [80 mg/dL])
Percentage of time with glucose below the lower limit of glycemic range (\<4.4 mmol/L) was assessed by the total time below the lower limit of glycemic range divided by the length of the assessment interval.
Time frame: Up to Week 16 (assessed at Weeks 7-8 in Period A and Weeks 15-16 in Period B)
Evaluation of Diurnal Glucose Exposure, Variability, and Stability
The diurnal glucose exposure is measured as the average diurnal glucose concentration, diurnal glucose variability is measured by interquartile range (IQR), that is, average distance between the 25th and the 75th point-wise percentiles and diurnal glucose stability is assessed in terms of the mean absolute rate of change (mmol/l), that is, the area under the absolute rate of change of the median curve (based on the median point values between two adjacent hourly basket intervals), divided by the length of the assessment interval.
Time frame: Up to Week 16 (assessed at Weeks 7-8 in Period A and Weeks 15-16 in Period B)
Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL]) in the Last Four Hours of Each Dosing Interval at Weeks 7 and 8 in Period A and Weeks 15 and 16 in Period B
Percentage of time with glucose within glycemic range (4.4-7.8 mmol/L) was assessed by the total time within glycemic range divided by the length of the assessment interval.
Time frame: Weeks 7-8 in Period A and Weeks 15-16 in Period B
Change in HbA1c From Baseline to Week 8 and 16
Time frame: Baseline, Week 8, 16
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 8 and 16
Time frame: Baseline, Week 8, 16
Change in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profile From Baseline to Week 8 and 16
Change in average of 7-point SMPG. 7-point SMPG was assessed starting with a measurement at before breakfast and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; at bedtime.
Time frame: Baseline, Week 8, 16
Change in Basal Insulin Daily Dose From Baseline to Week 8 and 16
Time frame: Baseline, Week 8, 16
Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline Up to Week 16
Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).
Time frame: Up to Week 16
| Milestone | HOE901-U300 Morning Then Evening | HOE901-U300 Evening Then Morning | Lantus Morning Then Evening | Lantus Evening Then Morning |
|---|---|---|---|---|
| Started | 15 | 15 | 15 | 14 |
| Completed | 14 | 15 | 14 | 13 |
| Not completed | 1 | 0 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Milestone | HOE901-U300 Morning Then Evening | HOE901-U300 Evening Then Morning | Lantus Morning Then Evening | Lantus Evening Then Morning |
|---|---|---|---|---|
| Started | 14 | 15 | 14 | 13 |
| Completed | 14 | 15 | 14 | 12 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 1 |
Percentage of time with glucose within glycemic range (4.4-7.8 mmol/L) was assessed by the total time within glycemic range divided by the length of the assessment interval.
| percentage of time | HOE901-U300 Combined | Lantus Combined |
|---|---|---|
| Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL]) | 31.75 ± 1.5 | 30.99 ± 1.58 |
Percentage of time with glucose above the upper limit of glycemic range (\>7.8 mmol/L) was assessed by the total time above the upper limit of glycemic range divided by the length of the assessment interval.
| percentage of time | HOE901-U300 Combined | Lantus Combined |
|---|---|---|
| Percentage of Time Above the Upper Limit of Glycemic Range (Greater Than [>] 7.8 mmol/L [(140 mg/dL]) | 58.24 ± 2.09 | 57.38 ± 2.2 |
Percentage of time with glucose below the lower limit of glycemic range (\<4.4 mmol/L) was assessed by the total time below the lower limit of glycemic range divided by the length of the assessment interval.
| percentage of time | HOE901-U300 Combined | Lantus Combined |
|---|---|---|
| Percentage of Time Below The Lower Limit of Glycemic Range (<4.4 mmol/L [80 mg/dL]) | 10.01 ± 1.02 | 11.64 ± 1.08 |
The diurnal glucose exposure is measured as the average diurnal glucose concentration, diurnal glucose variability is measured by interquartile range (IQR), that is, average distance between the 25th and the 75th point-wise percentiles and diurnal glucose stability is assessed in terms of the mean absolute rate of change (mmol/l), that is, the area under the absolute rate of change of the median curve (based on the median point values between two adjacent hourly basket intervals), divided by the length of the assessment interval.
| mmol/L | HOE901-U300 Combined | Lantus Combined |
|---|---|---|
| Diurnal Glucose Exposure | 8.869 ± 0.24 | 8.910 ± 0.26 |
| Diurnal Glucose Stability | 0.673 ± 0.03 | 0.703 ± 0.03 |
| Diurnal Glucose Variability | 4.931 ± 0.22 | 5.279 ± 0.23 |
Percentage of time with glucose within glycemic range (4.4-7.8 mmol/L) was assessed by the total time within glycemic range divided by the length of the assessment interval.
| percentage of time | HOE901-U300 Combined | Lantus Combined |
|---|---|---|
| Week 7, 8 (n=28, 27) | 32.08 ± 14.74 | 29.07 ± 13.82 |
| Week 15, 16 (n=29, 26) | 33.02 ± 13.48 | 28.70 ± 14.57 |
| percentage of hemoglobin | HOE901-U300 Combined | Lantus Combined |
|---|---|---|
| Week 8 (n= 29, 20) | -0.22 ± 0.48 | -0.23 ± 0.54 |
| Week 16 (n= 28, 27) | -0.44 ± 0.51 | -0.22 ± 0.58 |
| mmol/L | HOE901-U300 Combined | Lantus Combined |
|---|---|---|
| Week 8 (n=24, 23) | -0.89 ± 5.04 | -0.10 ± 5.81 |
| Week 16 (n= 24, 22) | -0.99 ± 5.27 | 0.78 ± 4.92 |
Change in average of 7-point SMPG. 7-point SMPG was assessed starting with a measurement at before breakfast and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; at bedtime.
| mmol/L | HOE901-U300 Combined | Lantus Combined |
|---|---|---|
| Week 8 | -0.39 ± 1.84 | 0.39 ± 1.54 |
| Week 16 | -0.47 ± 1.31 | 0.58 ± 2.13 |
| U/kg | HOE901-U300 Combined | Lantus Combined |
|---|---|---|
| Week 8 (n= 30, 29) | 0.06 ± 0.09 | 0.03 ± 0.09 |
| Week 16 (n=29, 27) | 0.05 ± 0.09 | 0.03 ± 0.08 |
Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).
| percentage of participants | HOE901-U300 Combined | Lantus Combined |
|---|---|---|
| Any Hypoglycemia Event: All Hypoglycemia | 100 | 100 |
| Severe Hypoglycemia: All Hypoglycemia | 3.3 | 10.3 |
| Documented Symptomatic: All Hypoglycemia | 93.3 | 96.6 |
| Asymptomatic: All Hypoglycemia | 86.7 | 96.6 |
| Probable Symptomatic: All Hypoglycemia | 16.7 | 27.6 |
| Relative: All Hypoglycemia | 0.0 | 6.9 |
| Severe and/or Confirmed: All Hypoglycemia | 100 | 100 |
| Any Hypoglycemia Event: Nocturnal Hypoglycemia | 80.0 | 93.1 |
| Severe Hypoglycemia: Nocturnal Hypoglycemia | 0.0 | 6.9 |
| Documented Symptomatic: Nocturnal Hypoglycemia | 66.7 | 79.3 |
| Asymptomatic: Nocturnal Hypoglycemia | 40.0 | 48.3 |
| Probable Symptomatic: Nocturnal Hypoglycemia | 3.3 | 10.3 |
| Relative: Nocturnal Hypoglycemia | 0.0 | 6.9 |
| Severe and/or Confirmed: Nocturnal Hypoglycemia | 80.0 | 93.1 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 16) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HOE901-U300 Combined | — | 1/30 (3.3%) | 18/30 (60%) |
| Lantus Combined | — | 0/29 (0%) | 17/29 (58.6%) |
| Event | HOE901-U300 Combined | Lantus Combined |
|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 1/30 | 0/29 |
| Event | HOE901-U300 Combined | Lantus Combined |
|---|---|---|
| NasopharyngitisInfections and infestations | 9/30 | 6/29 |
| HeadacheNervous system disorders | 2/30 | 4/29 |
| InfluenzaInfections and infestations | 2/30 | 3/29 |
| VomitingGastrointestinal disorders | 0/30 | 3/29 |
| DiarrhoeaGastrointestinal disorders | 3/30 | 1/29 |
| Implant site bruisingGeneral disorders | 3/30 | 0/29 |
| PyrexiaGeneral disorders | 3/30 | 2/29 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/30 | 2/29 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/30 | 2/29 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/30 | 2/29 |
Randomized population: all screened participants (who originally met inclusion criteria and signed informed consent) allocated to a treatment arm and recorded in Interactive Voice/Web Response System (IVRS/IWRS) database, regardless of whether treatment was used or not. Participants were analyzed in treatment arm to which they were randomized.
| Age, Continuous(years) | HOE901-U300 Morning Then Evening | HOE901-U300 Evening Then Morning | Lantus Morning Then Evening | Lantus Evening Then Morning | Total |
|---|---|---|---|---|---|
| Mean | 43.6 ± 14.6 | 46.2 ± 15.9 | 39.7 ± 12.5 | 47.6 ± 14.1 | 44.2 ± 14.3 |
| Sex: Female, Male(Participants) | HOE901-U300 Morning Then Evening | HOE901-U300 Evening Then Morning | Lantus Morning Then Evening | Lantus Evening Then Morning | Total |
|---|---|---|---|---|---|
| Female | 11 | 2 | 4 | 10 | 27 |
| Male | 4 | 13 | 11 | 4 | 32 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | HOE901-U300 Morning Then Evening | HOE901-U300 Evening Then Morning | Lantus Morning Then Evening | Lantus Evening Then Morning | Total |
|---|---|---|---|---|---|
| Mean | 27.5 ± 4.9 | 27.4 ± 5.0 | 28.3 ± 6.2 | 26.1 ± 5.1 | 27.3 ± 5.3 |
| Glycated Hemoglobin (HbA1c)(participants) | HOE901-U300 Morning Then Evening | HOE901-U300 Evening Then Morning | Lantus Morning Then Evening | Lantus Evening Then Morning | Total |
|---|---|---|---|---|---|
| Less Than (<) 8 | 11 | 14 | 12 | 12 | 49 |
| Greater Than or Equal to (>=) 8 | 4 | 1 | 3 | 2 | 10 |
| Duration of Diabetes(years) | HOE901-U300 Morning Then Evening | HOE901-U300 Evening Then Morning | Lantus Morning Then Evening | Lantus Evening Then Morning | Total |
|---|---|---|---|---|---|
| Median | 16.8 (3 to 48) | 23.9 (2 to 54) | 20.6 (5 to 47) | 16.7 (6 to 44) | 20.7 (2 to 54) |
| Basal Insulin Daily Dose(units per kilogram (U/kg)) | HOE901-U300 Morning Then Evening | HOE901-U300 Evening Then Morning | Lantus Morning Then Evening | Lantus Evening Then Morning | Total |
|---|---|---|---|---|---|
| Mean | 0.309 ± 0.086 | 0.283 ± 0.088 | 0.341 ± 0.100 | 0.267 ± 0.055 | 0.301 ± 0.087 |
| Total Insulin Daily Dose(U/kg) | HOE901-U300 Morning Then Evening | HOE901-U300 Evening Then Morning | Lantus Morning Then Evening | Lantus Evening Then Morning | Total |
|---|---|---|---|---|---|
| Mean | 0.600 ± 0.237 | 0.620 ± 0.179 | 0.677 ± 0.204 | 0.513 ± 0.115 | 0.603 ± 0.193 |
The record gives a start of Aug 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2015, 2 years after primary completion. A results delay was requested in Apr 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine